Rankings/Lila Sciences
Lila Sciences logo

Lila Sciences

NativeApplied AIPrivateUpdated November 15, 2026

The science superintelligence company applying AI to accelerate every dimension of scientific discovery.

Website
lila.ai
Founded
2023
CEO
Geoffrey von Maltzahn
HQ
Cambridge, MA, United States
Stage
Series A
Revenue
Not disclosed
Total Funding
$550M
Employees
201-500
Flag a data issue
Healthcare ToolsHealthcare
41.4Bluescore
Momentum61.1
Market MapStrong Distribution
Rank change (7d)▼ 31

Executive Summary

Updated Nov 1, 2026

What they do

  • Builds an AI platform that generates hypotheses and designs experiments across science fields
  • Runs robotic AI Science Factories that carry out experiments and feed results back to the models
  • Covers life sciences, chemistry and materials science, including mRNA and CAR-T therapy research

Why it matters

  • Tests AI predictions with real lab experiments, which addresses a key bottleneck in AI-driven R&D
  • Well funded: $550M raised, backed by Flagship, NVentures, General Catalyst and IQT
  • Reported in talks to raise about $2B at an $8.5B pre-money valuation, anchored by CalPERS and NVentures

Best fit

  • Large pharma and biotech R&D groups that want to run discovery programs with a partner
  • Chemicals and materials companies that want to speed up formulation and property discovery
  • Organizations willing to sign a strategic co-development partnership rather than buy software off the shelf

Watch-outs

  • No commercial customers or deployment terms have been publicly confirmed so far
  • The model is mostly partnered discovery, not a self-serve product buyers can license
  • Ownership of results and data-sharing terms in joint programs need careful negotiation

Products & Offerings

Scientific Superintelligence Platform

Lila's own AI reasoning engine that generates hypotheses, designs experiments and learns from lab results across life, chemical and materials sciences.

PlatformEnterpriseFlagship2025

AI Science Factories

Automated robotic labs that run experiments around the clock, directed by Lila's AI models; a 200,000-square-foot facility in Cambridge was reported under construction in mid-2026.

InfrastructureEnterpriseCore Platform2025

Scientific Agents for R&D Partners

Custom AI science agents built for large R&D companies that need high-quality data, strong security and the ability to scale for specific programs.

EnterpriseEnterpriseEmerging

RNA Discovery Engine

An autonomous discovery program that found ultra-stable mRNA designs and produced a CAR-T candidate that outperformed the leading therapy in non-human primates.

PlatformResearchPreview2026

Latest News

Analyst VerdictMonitor

Updated Nov 1, 2026

Lila Sciences has unusually deep funding and a credible team from Flagship Pioneering, and it has posted early results such as autonomously discovered mRNA and CAR-T work. However, its platform is only now reaching outside partners, and no enterprise customers are named. Pharma, biotech and materials R&D leaders should open exploratory talks about partnered programs, and wait for named deployments and clear commercial terms before committing major budgets.

Signal Provenance

Latest observation date and source for each signal category

Signal CategoryLast UpdatedSource
Funding Signals
Last funding round, Funding stage
Nov 14, 2026Cited web research
Hiring Velocity
Headcount, Headcount growth
Nov 15, 2026Research agents (estimate)
Technical Output
Research papers, GitHub activity
Nov 1, 2026Hugging Face Hub + news feed + research agents
News Sentiment
News mentions, News sentiment
Nov 15, 2026Verified news feed
Partnership Signals
Enterprise partnerships, Distribution partners
Nov 15, 2026Research agents (estimate)
Revenue Indicators
ARR estimate, Revenue growth
Nov 15, 2026Research agents (estimate)
Leadership Signals
CEO tenure, Founder-led
Nov 15, 2026Research agents (estimate)
Competitive Position
Category rank, Market share
NeverResearch agents (estimate)

Why this Bluescore?

6 dimensions, each scored 0–10 against all 250 companies. Each adds its weight × score to the Bluescore — see methodology

Lila Sciences's Bluescore of 41.4 rests most on Investment Momentum (5.0, 55th percentile) and Talent & Research (4.0, 50th percentile). Its weakest area is Data & Model Moat (3.3, 2nd percentile).

In plain English

Lila Sciences has a Bluescore of 41.4 out of 100, ranking #171 of 247, with its strongest showing in Investment Momentum, where it scores 5.0 of 10 and sits at the 55th percentile among the AI250. The biggest drag is Data & Model Moat, which scores 3.3 of 10 and places at the 2nd percentile among the AI250, so it adds only 6.3 of 19 points and leaves 12.7 unclaimed. The largest remaining opportunity is Product Depth, which carries a 21% weight, scores 3.7 of 10, and has 13.3 points still available, so improving it would move the Bluescore more than any other single dimension.

Written by AI from the scores below and checked against them; updated nightly.

D1 · Business Model & Revenue (21%)
4.4
+9.2 of 21 pts · 45th pct
D2 · Product Depth (21%)
3.7
+7.7 of 21 pts · 27th pct
D3 · Data & Model Moat (19%)
3.3
+6.3 of 19 pts · 2nd pct
D4 · Talent & Research (16%)
4.0
+6.3 of 16 pts · 50th pct
D5 · Customer Adoption (13%)
5.2
+6.8 of 13 pts · 50th pct
D6 · Investment Momentum (10%)
5.0
+5.0 of 10 pts · 55th pct

Traction Signals

Last Round

Series A

Risks

Updated Nov 1, 2026

No named enterprise customers yet, so value at scale is unproven
High
Reported $8.5B valuation creates pressure that could shift strategy toward in-house pipelines
Medium
Unclear ownership of IP and data when Lila co-develops discoveries with partners
High
Faces competition from well-funded autonomous-lab and AI-for-science rivals and big tech labs
Medium
Depends on building costly physical labs, which can delay access and capacity for partners
Medium
Feedback